Singular Genomics Systems, Inc.

Equities

OMIC

US82933R3084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:30:00 17/07/2024 BST			5-day change	1st Jan Change
8.22 ^USD	-5.30%		+7.87%	-40.45%

07-15	Singular Genomics Regains Nasdaq Compliance	MT
07-09	Goldman Sachs Adjusts Price Target on Singular Genomics Systems to $6.50 From $22.50, Maintains Neutral Rating	MT

Singular Genomics Systems, Inc. Reports Preliminary Unaudited Revenue Results for the Fourth Quarter of 2022

January 09, 2023 at 11:00 am

Singular Genomics Systems, Inc. reported preliminary unaudited revenue results for the fourth quarter of 2022. For the quarter, the company recognized approximately $700,000 in preliminary unaudited revenue.

Latest news about Singular Genomics Systems, Inc.

Singular Genomics Regains Nasdaq Compliance	07-15	MT
Goldman Sachs Adjusts Price Target on Singular Genomics Systems to $6.50 From $22.50, Maintains Neutral Rating	07-09	MT
Global markets live: Novo Nordisk, Apple, UPS, Eli Lilly, Qualcomm...	06-24
Singular Genomics Systems to Implement 1-For-30 Reverse Stock Split	06-21	MT
Goldman Sachs Trims Price Target on Singular Genomics Systems to $0.75 From $0.85, Maintains Neutral Rating	05-15	MT
Transcript : Singular Genomics Systems, Inc., Q1 2024 Earnings Call, May 14, 2024	05-14
Earnings Flash (OMIC) SINGULAR GENOMICS SYSTEMS Posts Q1 Revenue $0.4M, vs. Street Est of $0.7M	05-14	MT
Singular Genomics Systems, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
UBS Adjusts Singular Genomics Systems Price Target to $0.50 From $0.40, Maintains Neutral Rating	03-20	MT
Transcript : Singular Genomics Systems, Inc., Q4 2023 Earnings Call, Mar 18, 2024	03-18
Earnings Flash (OMIC) SINGULAR GENOMICS SYSTEMS Posts Q4 Revenue $1.1M, vs. Street Est of $1.04M	03-18	MT
Singular Genomics Systems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-18	CI
Singular Genomics Systems, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-18	CI
North American Morning Briefing : Investors -2-	03-18	DJ
Transcript : Singular Genomics Systems, Inc. - Special Call	02-05
Singular Genomics Systems, Inc. Showcases New G4X? Spatial Sequencer at AGBT and Announces Significant Advances in Throughput, Quality, and Usability for G4 Sequencing Platform	02-05	CI
Singular Genomics Unveils G4X Spatial Sequencer, Transforming the Landscape of In Situ Multiomic Analysis	02-05	CI
Goldman Sachs Trims Price Target on Singular Genomics Systems to $0.85 From $0.95, Maintains Neutral Rating	01-22	MT
Singular Genomics Systems, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter of 2023	01-08	CI
Singular Genomics Systems Expects 31% Growth in Q4 Revenue	01-08	MT
Transcript : Singular Genomics Systems, Inc., Q3 2023 Earnings Call, Nov 14, 2023	11-14
Earnings Flash (OMIC) SINGULAR GENOMICS SYSTEMS Posts Q3 Revenue $0.5M	11-14	MT
Singular Genomics Systems, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Fluent BioSciences Inc. Announces A Partnership with Singular Genomics	11-02	CI
UBS Adjusts Singular Genomics Systems Price Target to $0.40 From $0.90, Maintains Neutral Rating	12/10/23	MT

Chart Singular Genomics Systems, Inc.

Duration

Period

More charts

Company Profile

Singular Genomics Systems, Inc. is a life science technology company that develops next-generation sequencing (NGS) and multiomics technologies. The Company has developed NGS technology (Sequencing Engine), which is a platform technology for its products. The core of its Sequencing Engine consists of proprietary chemistry, including novel chemical compounds, polymers, and enzymes. Its active product development pipeline consists of two products, each of which is designed to leverage the Sequencing Engine and purpose-built to address different applications. Its first product, the G4 Sequencing Platform (G4), targets the NGS market. Its second product in development, G4X Spatial Sequencer, which leverages its sequencing technology, applying it as an in-situ readout for transcriptomics, proteomics and fluorescent H&E in tissue, with spatial context and on the same platform as the G4. The Company is also engaged in developing PX, which is a development-stage multiomics platform.

Sector

Biotechnology & Medical Research

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Singular Genomics Systems, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

8.22 USD

Average target price

6.5 USD

Spread / Average Target

-20.92%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SINGULAR GENOMICS SYSTEMS, INC.	-40.45%	20.3M
MODERNA, INC.	+24.74%	47.54B
IQVIA HOLDINGS INC.	-0.47%	41.96B
LONZA GROUP AG	+43.96%	41.55B
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	30.36B
ICON PUBLIC LIMITED COMPANY	+17.96%	27.61B
CELLTRION, INC.	-4.47%	28.7B
UNITED THERAPEUTICS CORPORATION	+50.73%	14.7B
MEDPACE HOLDINGS, INC.	+42.56%	13.51B
BIO-TECHNE CORPORATION	+1.46%	12.34B

Other Biotechnology & Medical Research